• 1
    Lichtenstein AH. Trans fatty acids, plasma lipid levels, and risk of developing cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation 1997; 95: 258890.
  • 2
    Siri-Tarino PW, Sun Q, Hu FB, Krauss RM. Saturated fatty acids and risk of coronary heart disease: modulation by replacement nutrients. Curr Atheroscler Rep 2010; 12: 38490.
  • 3
    Sudheendran S, Chang CC, Deckelbaum RJ. N-3 vs. saturated fatty acids: effects on the arterial wall. Prostaglandins Leukot Essent Fatty Acids 2010; 82: 2059.
  • 4
    Basu A, Devaraj S, Jialal I. Dietary factors that promote or retard inflammation. Arterioscler Thromb Vasc Biol 2006; 26: 9951001.
  • 5
    Funaki M. Saturated fatty acids and insulin resistance. J Med Invest 2009; 56: 8892.
  • 6
    Arslan Y, Kiziltan G. Nutrition-related cardiovascular risk factors in hemodialysis patients. J Ren Nutr 2010; 20: 18592.
  • 7
    Khoueiry G, Waked A, Goldman M et al. Dietary intake in hemodialysis patients does not reflect a heart healthy diet. J Ren Nutr 2011; 21: 43847.
  • 8
    Zoccali C. The obesity epidemics in ESRD: from wasting to waist? Nephrol Dial Transplant 2009; 24: 37680.
  • 9
    Huang X, Stenvinkel P, Qureshi AR et al. Essential polyunsaturated fatty acids, inflammation and mortality in dialysis patients. Nephrol Dial Transplant 2012; 27: 361520.
  • 10
    Paton CM, Ntambi JM. Biochemical and physiological function of stearoyl-CoA desaturase. Am J Physiol Endocrinol Metab 2009; 297: E2837.
  • 11
    Brown JM, Chung S, Sawyer JK et al. Inhibition of stearoyl-coenzyme A desaturase 1 dissociates insulin resistance and obesity from atherosclerosis. Circulation 2008; 118: 146775.
  • 12
    Matsui H, Yokoyama T, Sekiguchi K et al. Stearoyl-CoA desaturase-1 (SCD1) augments saturated fatty acid-induced lipid accumulation and inhibits apoptosis in cardiac myocytes. PLoS ONE 2012; 7: e33283.
  • 13
    Brown JM, Rudel LL. Stearoyl-coenzyme A desaturase 1 inhibition and the metabolic syndrome: considerations for future drug discovery. Curr Opin Lipidol 2010; 21: 1927.
  • 14
    de Jager DJ, Grootendorst DC, Jager KJ et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 2009; 302: 17829.
  • 15
    Zoccali C. Traditional and emerging cardiovascular and renal risk factors: an epidemiologic perspective. Kidney Int 2006; 70: 2633.
  • 16
    Zoccali C, Mallamaci F, Tripepi G. Inflammation and atherosclerosis in end-stage renal disease. Blood Purif 2003; 21: 2936.
  • 17
    Wanner C, Quaschning T. Dyslipidemia and renal disease: pathogenesis and clinical consequences. Curr Opin Nephrol Hypertens 2001; 10: 195201.
  • 18
    Robles NR, Macias JF. Cardiovascular risk in uremic patients: darkness after AURORA. Ren Fail 2010; 32: 26972.
  • 19
    Krog M, Ejerblad S, Agren A. Enzyme activities and adenine nucleotide content in aorta, heart muscle and skeletal muscle from uraemic rats. Br J Exp Pathol 1986; 67: 4318.
  • 20
    Huang X, Stenvinkel P, Qureshi AR et al. Clinical determinants and mortality predictability of stearoyl-CoA desaturase-1 activity indices in dialysis patients. J Intern Med 2012; doi: 10.1111/j.1365-2796.2012.02573.x. [Epub ahead of print]
  • 21
    Palmer SC, Navaneethan SD, Craig JC et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 2010; 153: 2333.
  • 22
    Jardine MJ, Kang A, Zoungas S et al. The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis. BMJ 2012; 344: e3533.